Quan Fu-Shi, Sailaja Gangadhara, Skountzou Ioanna, Huang Chunzi, Vzorov Andrei, Compans Richard W, Kang Sang-Moo
Department of Microbiology and Immunology, and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Rd, Atlanta, GA 30322, United States.
Vaccine. 2007 May 10;25(19):3841-50. doi: 10.1016/j.vaccine.2007.01.107. Epub 2007 Feb 15.
Extensive glycosylation and variable loops of the HIV envelope protein (Env) are reported to shield some neutralizing epitopes. Here, we investigated the immunogenicity of mutated HIV Envs presented in virus-like particles (VLPs). We immunized mice with simian human immunodeficiency virus (SHIV) VLPs containing mutant HIV Env with reduced glycosylation (3G), variable loop-deleted mutations (dV1V2), or combinations of both types of mutations (3G-dV2-1G), and evaluated immune responses. Immune sera from mice that received VLPs with modified HIV Envs (3G or dV1V2) showed higher neutralizing activities against the homologous HIV 89.6 virus as well as heterologous viruses when compared with wild type SHIV VLP-immunized mice. Lymphocytes from immunized mice produced HIV Env-specific cytokines, with the 3G-dV2-1G mutant producing high levels of cytokines. Interestingly, both dendritic cells and B cells were found to interact with VLPs suggesting that VLPs are effective immunogens. Therefore, this study suggests that VLPs containing modified HIV Env have the potential to be developed as candidate vaccines capable of inducing cellular and humoral immune responses including neutralizing activities.
据报道,HIV包膜蛋白(Env)广泛的糖基化和可变环会掩盖一些中和表位。在此,我们研究了病毒样颗粒(VLP)中呈现的突变HIV Env的免疫原性。我们用含有糖基化减少的突变HIV Env(3G)、可变环缺失突变(dV1V2)或两种突变组合(3G-dV2-1G)的猿猴人类免疫缺陷病毒(SHIV)VLP免疫小鼠,并评估免疫反应。与野生型SHIV VLP免疫的小鼠相比,接受具有修饰HIV Env(3G或dV1V2)的VLP的小鼠的免疫血清对同源HIV 89.6病毒以及异源病毒表现出更高的中和活性。免疫小鼠的淋巴细胞产生HIV Env特异性细胞因子,3G-dV2-1G突变体产生高水平的细胞因子。有趣的是,发现树突状细胞和B细胞都与VLP相互作用,这表明VLP是有效的免疫原。因此,本研究表明,含有修饰HIV Env的VLP有潜力被开发为能够诱导包括中和活性在内的细胞免疫和体液免疫反应的候选疫苗。